| 2.84 0 (0%) | 04-01 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually transmitted infections. Its pipeline further includes other diagnostic tests for various respiratory pathogens, such as a panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus. Established in 2013, Talis Biomedical Corporation is headquartered in Menlo Park, California.
Thu, 10 Oct 2024
Baker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical Corp - Yahoo Finance
Tue, 03 Sep 2024
Talis Biomedical agrees to $32.5 million settlement - Investing.com
Tue, 14 Nov 2023
Peninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives' - The Business Journals
Wed, 02 Aug 2023
Raymond Cheong Net Worth (2026) - GuruFocus
Fri, 13 Jan 2023
Talis Biomedical Corp (TLIS) Share Price Today | Talis Biomedical Corp (TLIS) Live NSE/BSE - Value Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|